Aperio Technologies, digital pathology for healthcare and life sciences, has received clearance from the US Food and Drug Administration (FDA) to market its ER and PR image analysis applications.
The FDA-cleared immunohistochemistry (IHC) image analysis applications are intended to be used as an aid to pathologists in detecting and quantifying ER (estrogen receptor) and PR (progesterone receptor) protein expressions from digital slide images created by Aperio's slide scanning systems.
Aperio's digital pathology system includes ScanScope scanners for creating digital slide images from microscope slides, the SpectrumTM digital pathology information management system and the specific image analysis applications that perform automated scoring of ER and PR breast cancer digital slides.
'The addition of FDA cleared ER/PR image analysis applications to previously cleared applications for HER2 provides clinicians and breast cancer patients with an entire-slide quantitative image analysis panel,' said Dirk Soenksen, chief executive officer of Aperio.
